Is Yttrium 90 Ibritumomab Tiuxetan safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Yttrium 90 Ibritumomab Tiuxetan. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of yttrium 90, the manufacturer and expert opinion recommend not administering the drug in women who wish to continue breastfeeding.[1] If the drug is administered to a nursing mother, breastfeeding should be discontinued. No restrictions on holding the infant after administration of the drug are necessary.[2]
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours and a decay energy of 2.28 MeV.
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Yttrium 90 Ibritumomab Tiuxetan” (LM1140). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.